Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
Summary
The NCI R01 supports discovery-stage projects to design and validate primary screening assays, implement high- or moderate-throughput screens (including virtual screening), and perform hit validation to identify small-molecule chemical probes or therapeutic leads targeting tumor cells or tumor-regulating immune cells. Applicants should focus on one or two stages with strong feasibility or preliminary data, collaborate with screening and medicinal chemistry experts for validation, and note that extensive lead optimization or clinical trials are out of scope.
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support discovery research for the identification of small molecules that function to elucidate the biology of cancer as chemical probes or function as activators or inhibitors of cancer target(s) for therapy. The scientific rationale for target selection must be provided. Small molecule tools or therapeutics may target tumor cells themselves or immune cells regulating tumor growth. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen . Assays may focus on specific biological targets or disease mechanisms relevant to cancer with the intent to screen for small molecule compounds to be used as probes for advancing knowledge about the known target(s), identifying new targets, or as pre-therapeutic leads; 2) screen implementation of high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches to identify initial screening hits; 3) hit validation , including implementation of secondary assays that are orthogonal to the primary assay, advanced cheminformatics analysis and initial medicinal chemistry inspection to prioritize the hit set, and follow-up assays to characterize mode and mechanism of action of the validated hits. It is anticipated that applications submitted in response to this NOFO will focus on one or two of the above stages, as each stage depends on success of the prior stage.
The small molecules for targets to be pursued must be relevant to understanding cancer biology, and/or for developing strategies for cancer prevention, diagnosis, treatment or clinical monitoring of treatment. In addition to targeting tumor cells themselves, applications targeting immune cells that regulate tumor development are appropriate for this NOFO. Small molecules that affect known immune checkpoint inhibitor pathways as well as small molecules that address emerging pathways involved in immune-mediated control of cancer are of interest. NCI also encourages projects focusing on small molecules that target pediatric fusion oncoproteins or that address novel targets in small cell lung cancer or pancreatic cancer. Applicants may find the NCI Developmental Therapeutics Program resources to be helpful. These include the NCI Program for Natural Product Discovery (NPNPD) Prefractionated Library which, as of March 2023, consisted of 500,000 natural product fractions that are available for screening.
Assessment of the reasons for failures of small molecule therapeutic agents in the clinic points to several areas for improvement of the drug discovery and development process that are pertinent to this NOFO:
Although outside the scope of this NOFO, extensive chemical optimization of hit molecules to generate highly selective probes or drugs is a logical next step. Databases of small-molecule probes for the study of disease-related biological processes and mechanisms in academic environments may be found in the Academic Drug Discovery Consortium or the Chemical Probes Portal . It is noted that probes may be the predecessors of drugs, but drugs with known off-target effects are seldom useful as probes of specific biological activities. Importantly, identification of chemical probe(s) for a given target opens the door to validation of the target in appropriate cellular, tissue, or animal models prior to clinical testing.
Projects for this NOFO may focus on one stage, or span several stages of discovery research:
1) development of the primary screen assay(s) and testing in an initial pilot screen
2) primary screen implementation
3) hit validation
For applications requesting support for more than one stage, demonstration of feasibility is needed, including strong justification and supporting preliminary data for the stages proposed. Areas to be considered for each stage are described below and given in greater detail in Section IV (Application and Submission Information, PHS 398 Research Plan).
Through this NOFO, NCI seeks to apply new knowledge and screening technologies to develop assays for novel cancer targets and pathways. Projects for assay development should emphasize the design and validation of creative approaches that have the potential to be used for chemical probe or drug discovery. Assays focusing on areas and approaches that have been extensively studied should be avoided unless a strong rationale is provided for additional studies in the projected area. Targets associated with rare and neglected cancers are encouraged.
Primary screening assays may be target-, pathway-, or phenotype-based . Some examples include:
Assay detection methods may include, but are not limited to:
In general, assays should adopt an adequate detection principle that results in the sensitive detection of even weak binders with expected low rates of false positives and false negatives. Complementary research including virtual screening may also be conducted to improve the likelihood of success and cost-effectiveness.
If achievable, pilot screening for target validation from a small compound library (e.g., LOPAC1280 ), should be proposed as a highly desirable validation step for translation of the assay to HTS. Instructions for the design and testing of a primary assay may be found in Section IV (Application and Submission Information, PHS 398 Research Plan).
Projects focusing on screen implementation are encouraged to provide preliminary data demonstrating that a primary screen has been developed, fully characterized, and tested in a pilot format. See Section IV for further details on expected information prior to the Primary Screen Implementation stage.
Virtual Screening (VS)
In addition to screens of chemical libraries, NCI, through this NOFO, seeks to make use of large, publicly available databases of 3D protein structures, genomic metabolomic, and proteomic data, and virtual small molecule libraries, combined with computational approaches to accelerate the discovery of novel and potential drug candidates based on specific molecular targets. Projects proposing the use of VS, either ligand-based screening or receptor-based screening, must collaborate with hit assay validation and medicinal chemistry experts for experimental testing of the proposed in silico hits.
VS techniques may involve computational approaches that include, but are not limited to:
Applicants are encouraged to collaborate with an experienced screening facility, particularly if high throughput screening (HTS) is planned. The screening facility may provide advice such as identification and selection of commercial HTS assay reagents, and suitable HTS assay format and readout. In addition, the screening facility may be able to aid in adapting assays to an HTS format (e.g., 1536-well or 384-well microplate). Further, the researchers might seek advice from the screening laboratory about orthogonal assays to validate the screening hits. Phenotypic screening should only be proposed if target deconvolution is included in the application or if there is a strong association between the mechanisms that drive the phenotypic assay, the preclinical disease model, and the human disease.
Technical resources about assay development and screening include the online comprehensive guidebook ( Assay Guidance Manual ), assay protocols deposited on the PubChem BioAssay data base , ASSAY and Drug Development Technologies , a peer-reviewed bi-monthly journal, and SLAS Discovery .
For the purposes of this NOFO, a “hit” is defined as a compound that has the desired activity in a compound screen and whose activity is confirmed upon retesting in orthogonal assays.
Hits from a primary screen may be systematically assessed using a cascade of follow-up assays to remove false positives. Primary HTS assays typically generate hundreds to thousands of hits, many of which are false positives or are chemically intractable. Hits from smaller scale primary screens are also likely to generate false positives or chemically intractable molecules that require additional screens. Post-primary screening assays may include:
In addition, investigators should conduct advanced cheminformatics analysis and medicinal chemistry inspection to prioritize the hit set. It is expected that the investigators will test powder samples of hit compounds and commercially available analog compounds during the hit validation stage. Investigators should verify the structure of hits using a combination of analytical methods and, if possible, re-synthesis of select hits.
The following types of studies are beyond the scope of this NOFO. Applications proposing such studies will be considered non-responsive and will not be reviewed.
See Section VIII. Other Information for award authorities and regulations.
Source
Dates
Eligibility
Keywords
Supporting Links
Documents
Similar Opportunities
-
Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
Department of Health and Human Services
-
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
Department of Health and Human Services ▸ National Institutes of Health
-
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
Department of Health and Human Services ▸ National Institutes of Health
-
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
Department of Health and Human Services ▸ National Institutes of Health
-
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
Department of Health and Human Services ▸ National Institutes of Health
Find tens of thousands more opportunities — free
Scout accounts are free. Sign up to browse the full funding database, unlock the solicitation links and documents for this opportunity, and see how well each one fits your organization.
-
Tens of thousands of funding opportunities
Search and filter every grant and solicitation in Scout — all free, no credit card required.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Save opportunities & track deadlines
Keep the opportunities that fit in one place and stay ahead of every due date.
Already have an account? Sign In
Trusted by 500+ Happy Customers